THE CAUSATIVE AGENT OF THE ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), AN INEVITABLY FATAL DISEASE, APPEARS TO BE A MEMBER OF A CLOSELY RELATED FAMILY OF RNA VIRUSES CALLED HUMAN T-LYMPHOTROPIC VIRUS TYPE III (HTLV-III) OR LYMPHADENOPATHY-ASSOCIATED

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 4686
Amount: $50,000.00
Phase: Phase I
Program: SBIR
Awards Year: 1986
Solitcitation Year: N/A
Solitcitation Topic Code: N/A
Solitcitation Number: N/A
Small Business Information
Biogen Research Corp
14 Cambridge Center, Cambridge, MA, 02142
Duns: N/A
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 RICHARD A FISHER
 PRINCIPAL INVESTIGATOR
 (617) 864-8900
Business Contact
Phone: () -
Research Institution
N/A
Abstract
THE CAUSATIVE AGENT OF THE ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), AN INEVITABLY FATAL DISEASE, APPEARS TO BE A MEMBER OF A CLOSELY RELATED FAMILY OF RNA VIRUSES CALLED HUMAN T-LYMPHOTROPIC VIRUS TYPE III (HTLV-III) OR LYMPHADENOPATHY-ASSOCIATED VIRUS (LAV). THE HOST RANGE OF THIS VIRUS IS DEFINED BY CELLS WHICH BEAR THE SURFACE GLYCOPROTEIN T4. INDEED, ALL AVAILABLE EVIDENCE INDICATES THAT T4 IS THE MEMBRANE-ANCHORED RECEPTOR FOR HTLV-III/LAV. CLINICAL STUDIES SUGGEST THAT THE PROGRESSION OF DISEASE CAN BE CORRELATED WITH DEPLETION OF A FUNCTIONAL CLASS OF IMMUNE SYSTEM REGULATORY CELLS, T-HELPER LYMPHOCYTES, WHICH DISPLAY THE T4 SURFACE PROTEIN AND THAT THIS T-CELL DEPLETION, WITH ENSUING IMMUNOLOGICAL COMPROMISE, MIGHT RESULT FROM RECURRENT CYCLES OF INFECTION AND LYTIC GROWTH. THIS SUGGESTS A THERAPEUTIC STRATEGY FOR THE TREATMENT OF AIDS AND PRE-AIDS: RECOMBINANT SOLUBLE T4 PROTEIN WILL SERVTO SEQUESTER FREE HTLV-III/LAV BY ACTING AS SOLUBLE VIRUS RECEPTOR. THIS WILL IN TURN RETARD OF COMPLETELY INHIBIT VIRUS GROWTH IN INFECTED INDIVIDUALS.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government